Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

546 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double-Blind Withdrawal Study.
Coates LC, Pillai SG, Tahir H, Valter I, Chandran V, Kameda H, Okada M, Kerr L, Alves D, Park SY, Adams DH, Gallo G, Hufford MM, Hojnik M, Mease PJ, Kavanaugh A; SPIRIT-P3 Study Group. Coates LC, et al. Among authors: kameda h. Arthritis Rheumatol. 2021 Sep;73(9):1663-1672. doi: 10.1002/art.41716. Epub 2021 Aug 6. Arthritis Rheumatol. 2021. PMID: 33682378 Free PMC article.
Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study).
Yamanaka H, Tanaka Y, Inoue E, Hoshi D, Momohara S, Hanami K, Yunoue N, Saito K, Amano K, Kameda H, Takeuchi T. Yamanaka H, et al. Among authors: kameda h. Mod Rheumatol. 2011 Apr;21(2):122-33. doi: 10.1007/s10165-010-0366-7. Epub 2010 Oct 16. Mod Rheumatol. 2011. PMID: 20953815 Free PMC article. Clinical Trial.
Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.
Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, Nakajima A, Saito K, Takeno M, Atsumi T, Tohma S, Ito S, Tamura N, Fujii T, Sawada T, Ida H, Hashiramoto A, Koike T, Ishigatsubo Y, Eguchi K, Tanaka Y, Takeuchi T, Miyasaka N, Harigai M; REAL Study Group. Komano Y, et al. Among authors: kameda h. J Rheumatol. 2011 Jul;38(7):1258-64. doi: 10.3899/jrheum.101009. Epub 2011 Apr 15. J Rheumatol. 2011. PMID: 21498482
Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study).
Takeuchi T, Tanaka Y, Kaneko Y, Tanaka E, Hirata S, Kurasawa T, Kubo S, Saito K, Shidara K, Kimura N, Nagasawa H, Kameda H, Amano K, Yamanaka H. Takeuchi T, et al. Among authors: kameda h. Mod Rheumatol. 2012 Jun;22(3):327-38. doi: 10.1007/s10165-011-0516-6. Epub 2011 Sep 7. Mod Rheumatol. 2012. PMID: 21898074 Free PMC article.
A retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients: a report from the Ad Hoc Committee for Safety of Biological DMARDs of the Japan College of Rheumatology.
Takamura A, Hirata S, Nagasawa H, Kameda H, Seto Y, Atsumi T, Dohi M, Koike T, Miyasaka N, Harigai M. Takamura A, et al. Among authors: kameda h. Mod Rheumatol. 2013 Mar;23(2):297-303. doi: 10.1007/s10165-012-0658-1. Epub 2012 May 10. Mod Rheumatol. 2013. PMID: 22572888
Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: an open, randomized, controlled trial.
Kurasawa T, Nagasawa H, Kishimoto M, Amano K, Takeuchi T, Kameda H. Kurasawa T, et al. Among authors: kameda h. Mod Rheumatol. 2014 Jul;24(4):561-6. doi: 10.3109/14397595.2013.844886. Epub 2013 Nov 5. Mod Rheumatol. 2014. PMID: 24252035 Clinical Trial.
Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52.
Izumi K, Kaneko Y, Yasuoka H, Seta N, Kameda H, Kuwana M, Takeuchi T. Izumi K, et al. Among authors: kameda h. Mod Rheumatol. 2015 Jan;25(1):31-7. doi: 10.3109/14397595.2014.897793. Epub 2014 Apr 1. Mod Rheumatol. 2015. PMID: 24684408
546 results